All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aripiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Abilify Maintena
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2020
Details:
Otsuka Pharmaceutical created ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in the U.S. and E.U. for the treatment of adult schizophrenia.